Patient perspectives on videoconferencing-based treatment for alcohol use disorders

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Objective: To examine if monocyte and macrophage activity may be on the mechanistic pathway to non-AIDS comorbidity by investigating the associations between plasma-soluble CD163 (sCD163) and incident non-AIDS comorbidities in well treated HIV-infected individuals.

Design: Prospective single-center cohort study.

Methods: Plasma sCD163 was quantified by ELISA technique at study entry in 2004/2005, and non-AIDS comorbidity was identified by International Classification of Disease Tenth revision diagnosis codes and registry linkage in 2014/2015. Associations between sCD163 and incident comorbidity was examined using multivariable Cox proportional hazards models adjusted for pertinent covariates.

Results: In HIV-1-infected individuals (n = 799), the highest quartile of plasma sCD163 was associated with incident chronic lung disease [adjusted hazard ratio (aHR), 3.2; 95% confidence interval (CI): 1.34; 7.46] and incident chronic kidney disease (aHR, 10.94; 95% CI: 2.32; 51.35), when compared with lowest quartiles. Further, (every 1 mg) increase in plasma sCD163 was positively correlated with incident liver disease (aHR, 1.12; 95% CI: 1.05; 1.19). The sCD163 level was not associated with incident cancer, cardiovascular disease or diabetes mellitus.

Conclusion: sCD163 was independently associated with incident chronic kidney disease, chronic lung disease and liver disease in treated HIV-1-infected individuals, suggesting that monocyte/macrophage activation may be involved in the pathogenesis of non-AIDS comorbidity and a potential target for therapeutic intervention.
OriginalsprogEngelsk
TidsskriftAlcoholism Treatment Quarterly
Vol/bind35
Udgave nummer4
Sider (fra-til)344-358
ISSN0734-7324
DOI
StatusUdgivet - 2017

Fingeraftryk

Comorbidity
Alcohols
Confidence Intervals
Lung Diseases
HIV-1
Liver Diseases
Macrophage Activation
International Classification of Diseases
Proportional Hazards Models
Registries
Diabetes Mellitus
Cohort Studies
Macrophages
HIV
Neoplasms

Citer dette

@article{1c9c88e4b696402f8e9d661bc083f21c,
title = "Patient perspectives on videoconferencing-based treatment for alcohol use disorders",
abstract = "Objective: To examine if monocyte and macrophage activity may be on the mechanistic pathway to non-AIDS comorbidity by investigating the associations between plasma-soluble CD163 (sCD163) and incident non-AIDS comorbidities in well treated HIV-infected individuals.Design: Prospective single-center cohort study.Methods: Plasma sCD163 was quantified by ELISA technique at study entry in 2004/2005, and non-AIDS comorbidity was identified by International Classification of Disease Tenth revision diagnosis codes and registry linkage in 2014/2015. Associations between sCD163 and incident comorbidity was examined using multivariable Cox proportional hazards models adjusted for pertinent covariates.Results: In HIV-1-infected individuals (n = 799), the highest quartile of plasma sCD163 was associated with incident chronic lung disease [adjusted hazard ratio (aHR), 3.2; 95{\%} confidence interval (CI): 1.34; 7.46] and incident chronic kidney disease (aHR, 10.94; 95{\%} CI: 2.32; 51.35), when compared with lowest quartiles. Further, (every 1 mg) increase in plasma sCD163 was positively correlated with incident liver disease (aHR, 1.12; 95{\%} CI: 1.05; 1.19). The sCD163 level was not associated with incident cancer, cardiovascular disease or diabetes mellitus.Conclusion: sCD163 was independently associated with incident chronic kidney disease, chronic lung disease and liver disease in treated HIV-1-infected individuals, suggesting that monocyte/macrophage activation may be involved in the pathogenesis of non-AIDS comorbidity and a potential target for therapeutic intervention.",
author = "Tarp, {Kristine H{\ae}strup Hindkj{\ae}r} and Nielsen, {Anette S{\o}gaard}",
year = "2017",
doi = "10.1080/07347324.2017.1348785",
language = "English",
volume = "35",
pages = "344--358",
journal = "Alcoholism Treatment Quarterly",
issn = "0734-7324",
publisher = "Heinemann",
number = "4",

}

Patient perspectives on videoconferencing-based treatment for alcohol use disorders. / Tarp, Kristine Hæstrup Hindkjær ; Nielsen, Anette Søgaard.

I: Alcoholism Treatment Quarterly, Bind 35, Nr. 4, 2017, s. 344-358.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Patient perspectives on videoconferencing-based treatment for alcohol use disorders

AU - Tarp, Kristine Hæstrup Hindkjær

AU - Nielsen, Anette Søgaard

PY - 2017

Y1 - 2017

N2 - Objective: To examine if monocyte and macrophage activity may be on the mechanistic pathway to non-AIDS comorbidity by investigating the associations between plasma-soluble CD163 (sCD163) and incident non-AIDS comorbidities in well treated HIV-infected individuals.Design: Prospective single-center cohort study.Methods: Plasma sCD163 was quantified by ELISA technique at study entry in 2004/2005, and non-AIDS comorbidity was identified by International Classification of Disease Tenth revision diagnosis codes and registry linkage in 2014/2015. Associations between sCD163 and incident comorbidity was examined using multivariable Cox proportional hazards models adjusted for pertinent covariates.Results: In HIV-1-infected individuals (n = 799), the highest quartile of plasma sCD163 was associated with incident chronic lung disease [adjusted hazard ratio (aHR), 3.2; 95% confidence interval (CI): 1.34; 7.46] and incident chronic kidney disease (aHR, 10.94; 95% CI: 2.32; 51.35), when compared with lowest quartiles. Further, (every 1 mg) increase in plasma sCD163 was positively correlated with incident liver disease (aHR, 1.12; 95% CI: 1.05; 1.19). The sCD163 level was not associated with incident cancer, cardiovascular disease or diabetes mellitus.Conclusion: sCD163 was independently associated with incident chronic kidney disease, chronic lung disease and liver disease in treated HIV-1-infected individuals, suggesting that monocyte/macrophage activation may be involved in the pathogenesis of non-AIDS comorbidity and a potential target for therapeutic intervention.

AB - Objective: To examine if monocyte and macrophage activity may be on the mechanistic pathway to non-AIDS comorbidity by investigating the associations between plasma-soluble CD163 (sCD163) and incident non-AIDS comorbidities in well treated HIV-infected individuals.Design: Prospective single-center cohort study.Methods: Plasma sCD163 was quantified by ELISA technique at study entry in 2004/2005, and non-AIDS comorbidity was identified by International Classification of Disease Tenth revision diagnosis codes and registry linkage in 2014/2015. Associations between sCD163 and incident comorbidity was examined using multivariable Cox proportional hazards models adjusted for pertinent covariates.Results: In HIV-1-infected individuals (n = 799), the highest quartile of plasma sCD163 was associated with incident chronic lung disease [adjusted hazard ratio (aHR), 3.2; 95% confidence interval (CI): 1.34; 7.46] and incident chronic kidney disease (aHR, 10.94; 95% CI: 2.32; 51.35), when compared with lowest quartiles. Further, (every 1 mg) increase in plasma sCD163 was positively correlated with incident liver disease (aHR, 1.12; 95% CI: 1.05; 1.19). The sCD163 level was not associated with incident cancer, cardiovascular disease or diabetes mellitus.Conclusion: sCD163 was independently associated with incident chronic kidney disease, chronic lung disease and liver disease in treated HIV-1-infected individuals, suggesting that monocyte/macrophage activation may be involved in the pathogenesis of non-AIDS comorbidity and a potential target for therapeutic intervention.

U2 - 10.1080/07347324.2017.1348785

DO - 10.1080/07347324.2017.1348785

M3 - Journal article

VL - 35

SP - 344

EP - 358

JO - Alcoholism Treatment Quarterly

JF - Alcoholism Treatment Quarterly

SN - 0734-7324

IS - 4

ER -